Device Trial Radar · NCT04598802
COvera in BRAnch Registry
Last checked: Nov 20, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Oct 16, 2020
Primary completion
Oct 30, 2022
Study completion Oct 30, 2022
Sponsor
- Lead sponsor
- IRCCS San RaffaeleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 22, 2020
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the registry is to evaluate the peri-operative and short-, mid- and long-term outcomes of the Bard Covera Plus (Tempe, Arizona, USA) for the treatment of atherosclerotic aorto-iliac aneurysm in combination with a multibranched endograft
Conditions
- Aneurysm
Interventions
covered stentDevice
atherosclerotic aorto-iliac aneurysm
Primary outcomes
What the sponsor says the trial is designed to measure.
- technical successTime frame: 30 days
- Branch instabilityTime frame: 30 days
- Primary clinical successTime frame: 30 days
Locations
33 sites in 2 countries. Site status is shown where the registry gives one.
University Heart & Vascular Center
Hamburg, Germany
Ludwig-Maximilians University Hospital
Munich, Germany
Ospedale di Asti
Asti, Italy
30 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.